Business Context and Reporting Period
This Form 8-K Current Report was filed by Vistagen Therapeutics, Inc. (VTGN) on October 27, 2025. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial details provided relate to the compensation package for the newly appointed director:
- Stock Options: 35,200 shares granted.
- Exercise Price: $3.90 per share (equal to the closing price on the appointment date).
- Vesting Schedule: Equal annual installments over three years, beginning one year after the appointment date.
- Term: Ten years.
Material Changes
The material change reported is the addition of Mr. Paul R. Edick to the Board of Directors. He was appointed to serve until the next annual meeting of stockholders or until his successor is elected. Additionally, he was appointed to the Audit and Compensation Committees. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on business outlook, or discussion of operational risks. The document notes the execution of an Indemnification Agreement, which requires the Company to indemnify Mr. Edick to the fullest extent permitted under Nevada law against liabilities arising from his position as a director.
Investor Verification Checklist
- Verify the current stock price of VTGN relative to the $3.90 exercise price of the new options.
- Review the full text of the Indemnification Agreement (Exhibit 10.1) for specific liability caps or exclusions.
- Confirm the total number of outstanding options under the 2019 Omnibus Equity Incentive Plan to assess dilution impact.
- Check the press release (Exhibit 99.1) for any additional context regarding Mr. Edick's background or strategic value.